Cellectis Announces Poster Presentation on BALLI-01 at the
European Hematology Association (EHA) 2023
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS),
a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, today announced the release of an abstract, which was
accepted for presentation at the European Hematology Association
(EHA) Hybrid Congress, taking place on June 8-15, 2023 in
Frankfurt, Germany.
Cellectis will present, in a poster session,
updated clinical and translational data on its BALLI-01 clinical
trial (evaluating UCART22) in patients with relapsed/refractory
B-cell acute lymphoblastic Leukemia (r/r B-ALL).
“Cellectis is excited to present updated
clinical and translational data from its BALLI-01 clinical trial
(evaluating UCART22) in patients with relapsed/refractory B-cell
acute lymphoblastic leukemia. These data are very encouraging for
patients who have limited, if any, treatment options, especially
for those who have failed prior CD19 directed CAR T-cell therapy
and allogeneic stem cell transplant” said Mark Frattini, M.D.,
Ph.D., Chief Medical Officer at Cellectis.
Poster Presentation:
BALLI-01 investigation UCART22 product candidate in r/r
B-ALL
The abstract includes preliminary clinical data
from the Phase 1/2a, open label dose-escalation BALLI-01, in
patients with r/r B-ALL having received UCART22 following
lymphodepletion (LD) with either fludarabine, cyclophosphamide (FC)
or FC with alemtuzumab (FCA).
The data show that UCART22 was well tolerated
and clinical responses were achieved. UCART22 continues to have a
good safety profile, with no serious treatment emergent adverse
events (TEAEs) or DLTs reported. Overall, these data support the
safety and preliminary efficacy of UCART22 in a heavily pretreated
r/r B-ALL population.
UCART22 is a genetically modified allogeneic
T-cell product manufactured from healthy donor cells. Donor-derived
T-cells are transduced using a lentiviral vector to express the
anti-CD22 chimeric antigen receptor (CAR) and are further modified
using Cellectis’ TALEN® technology to disrupt the T-cell receptor
alpha constant (TRAC) and CD52 genes to minimize risk of
graft-vs-host disease (GvHD) and allow use of an anti-CD52 antibody
for lymphodepletion (LD).
Presentation Details:
Title: Updated Results of the Phase I
BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell
Product, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell
Acute Lymphoblastic Leukemia (B-ALL)
Presenter: Nicolas Boissel, M.D., Ph.D.,
Hôpital St Louis, Assistance Publique – Hôpitaux de Paris, Paris,
France
Abstract and logistic details are available on
www.ehaweb.org
About
Cellectis Cellectis is a clinical-stage
biotechnology company using its pioneering gene-editing platform to
develop life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with over
23 years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS). For more information, visit www.cellectis.com. Follow
Cellectis on social media: @cellectis, LinkedIn and
YouTube
Forward-looking
Statements This press release contains
“forward-looking” statements within the meaning of applicable
securities laws, including the Private Securities Litigation Reform
Act of 1995. Forward-looking statements may be identified by words
such as “anticipate,” “believe,” “intend”, “expect,” “plan,”
“scheduled,” “could,” “would” and “will,” or the negative of these
and similar expressions. These forward-looking statements, which
are based on our management’s current expectations and assumptions
and on information currently available to management.
Forward-looking statements include statements about the timing of
our presentation of clinical and translational data, the
advancement, timing and progress of clinical trials (including with
respect to patient enrollment and follow-up), the adequacy and
continuity of supply of clinical supply and alemtuzumab, the
ability of an anti-CD52 as alemtuzumab to improve any efficacy and
the potential benefit of UCART product candidates. These
forward-looking statements are made in light of information
currently available to us and are subject to numerous risks and
uncertainties, including with respect to the numerous risks
associated with biopharmaceutical product candidate development.
With respect to our cash runway, our operating plans, including
product development plans, may change as a result of various
factors, including factors currently unknown to us. Furthermore,
many other important factors, including those described in our
Annual Report on Form 20-F and the financial report (including the
management report) for the year ended December 31, 2022 and
subsequent filings Cellectis makes with the Securities Exchange
Commission from time to time, as well as other known and unknown
risks and uncertainties may adversely affect such forward-looking
statements and cause our actual results, performance or
achievements to be materially different from those expressed or
implied by the forward-looking statements. Except as required by
law, we assume no obligation to update these forward-looking
statements publicly, or to update the reasons why actual results
could differ materially from those anticipated in the
forward-looking statements, even if new information becomes
available in the future.
For further information, please
contact:
Media contact: Pascalyne
Wilson, Director, Communications, +33 (0)7 76 99 14 33,
media@cellectis.com
Investor Relation
contacts: Arthur Stril, Chief Business
Officer, +1 (347) 809 5980,
investors@cellectis.com Ashley R. Robinson,
LifeSci Advisors, +1 617 430 7577
- EHA2023_Curtain Raiser_PR(1)
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
From Apr 2024 to May 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
From May 2023 to May 2024